Literature DB >> 33745181

Corrigendum.

.   

Abstract

Year:  2021        PMID： 33745181      PMCID： PMC8173638          DOI： 10.1111/apt.16332

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  2 in total

1.  A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.

Authors:  Parambir S Dulai; Aurelien Amiot; Laurent Peyrin-Biroulet; Vipul Jairath; Melanie Serrero; Jerome Filippi; Siddharth Singh; Benjamin Pariente; Edward V Loftus; Xavier Roblin; Sunanda Kane; Anthony Buisson; Corey A Siegel; Yoram Bouhnik; William J Sandborn; Karen Lasch; Maria Rosario; Brian G Feagan; Daniela Bojic; Caroline Trang-Poisson; Bo Shen; Romain Altwegg; Bruce E Sands; Jean-Frederic Colombel; Franck Carbonnel
Journal:  Aliment Pharmacol Ther       Date:  2019-12-22       Impact factor: 8.171

2.  Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.

Authors:  Matthew Bohm; Ronghui Xu; Yiran Zhang; Sashidhar Varma; Monika Fischer; Gursimran Kochhar; Brigid Boland; Siddharth Singh; Robert Hirten; Ryan Ungaro; Eugenia Shmidt; Karen Lasch; Vipul Jairaith; David Hudesman; Shannon Chang; Dana Lukin; Arun Swaminath; Bruce E Sands; Jean-Frederic Colombel; Sunanda Kane; Edward V Loftus; Bo Shen; Corey A Siegel; William J Sandborn; Parambir S Dulai
Journal:  Aliment Pharmacol Ther       Date:  2020-07-13       Impact factor: 9.524
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.